297 related articles for article (PubMed ID: 21227994)
1. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
[TBL] [Abstract][Full Text] [Related]
2. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
3. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2011 Feb; 49(2):630-7. PubMed ID: 21159940
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
[TBL] [Abstract][Full Text] [Related]
5. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
[TBL] [Abstract][Full Text] [Related]
6. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.
Jang MJ; Shin JH; Lee WG; Kim MN; Lee K; Lee HS; Lee MK; Chang CL; Jang HC; Song ES; Kim SH; Shin MG; Suh SP; Ryang DW
Ann Lab Med; 2013 May; 33(3):167-73. PubMed ID: 23667842
[TBL] [Abstract][Full Text] [Related]
7. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].
Dalyan Cilo B; Topaç T; Ağca H; Sağlam S; Efe K; Ener B
Mikrobiyol Bul; 2018 Jan; 52(1):35-48. PubMed ID: 29642828
[TBL] [Abstract][Full Text] [Related]
9. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Moet GJ; Jones RN
J Clin Microbiol; 2010 May; 48(5):1592-9. PubMed ID: 20335424
[TBL] [Abstract][Full Text] [Related]
10. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Pfaller MA; Bustamante B; Canton E; Fothergill A; Fuller J; Gonzalez GM; Lass-Flörl C; Lockhart SR; Martin-Mazuelos E; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Szeszs MW; St-Germain G; Bonfietti LX; Guarro J; Turnidge J
Antimicrob Agents Chemother; 2014; 58(4):2006-12. PubMed ID: 24419346
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing and the Clinical Laboratory Standards Institute BMD method for non-Candida albicans and non-C. tropicalis bloodstream isolates from eleven tertiary hospitals in São Paulo state, Brazil.
Purisco SU; Martins MA; Szeszs MW; Castro e Silva DM; Pukinskas SR; Bonfietti LX; Baez AA; Melhem MS
FEMS Yeast Res; 2012 Dec; 12(8):890-6. PubMed ID: 22883021
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Six Antifungal Susceptibilities of 11
Lee H; Choi SH; Oh J; Koo J; Lee HJ; Cho SI; Shin JH; Lee HK; Kim SY; Lee CH; Kim YR; Sohn YH; Kim WJ; Ryu SW; Sung GH; Kim J
Microbiol Spectr; 2022 Apr; 10(2):e0125321. PubMed ID: 35384691
[TBL] [Abstract][Full Text] [Related]
14. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
[TBL] [Abstract][Full Text] [Related]
15. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in
Espinel-Ingroff A; Turnidge J; Alastruey-Izquierdo A; Botterel F; Canton E; Castro C; Chen YC; Chen Y; Chryssanthou E; Dannaoui E; Garcia-Effron G; Gonzalez GM; Govender NP; Guinea J; Kidd S; Lackner M; Lass-Flörl C; Linares-Sicilia MJ; López-Soria L; Magobo R; Pelaez T; Quindós G; Rodriguez-Iglesia MA; Ruiz MA; Sánchez-Reus F; Sanguinetti M; Shields R; Szweda P; Tortorano A; Wengenack NL; Bramati S; Cavanna C; DeLuca C; Gelmi M; Grancini A; Lombardi G; Meletiadis J; Negri CE; Passera M; Peman J; Prigitano A; Sala E; Tejada M
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323038
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis.
Marcos-Arias C; Eraso E; Madariaga L; Carrillo-Muñoz AJ; Quindós G
Mycopathologia; 2012 Jan; 173(1):35-46. PubMed ID: 21842426
[TBL] [Abstract][Full Text] [Related]
17. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ
J Clin Microbiol; 2003 Apr; 41(4):1440-6. PubMed ID: 12682127
[TBL] [Abstract][Full Text] [Related]
18. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
19. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ellis D; Tullio V; Rodloff A; Fu W; Ling TA;
J Clin Microbiol; 2010 Apr; 48(4):1366-77. PubMed ID: 20164282
[TBL] [Abstract][Full Text] [Related]
20. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
Pfaller MA; Messer SA; Boyken L; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2008 Feb; 46(2):551-9. PubMed ID: 18094129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
